1. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program;Passiglia;Lung Cancer,2024
2. Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer;Thummalapalli;JCO Precis Oncol,2023
3. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: a multicenter real-world experience from the compassionate use program in Germany;Stratmann;Eur J Cancer,2024
4. Brief report: real-world efficacy and safety of sotorasib in U.S. Veterans with KRAS G12C-mutated NSCLC;Zhou;JTO Clin Res Rep,2024
5. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial;de Langen;Lancet,2023